Rivastigmine Transdermal System Patch, Extended Release
Product Images NDC 63629-2066

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Rivastigmine Transdermal System (NDC 63629-2066). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636292066)

Label for Rivastigmine Transdermal System 9.5 mg/24 hours patch by Bryant Ranch Prepack. The label includes dosage strength, storage instructions, usage directions, a barcode, and the BRP Pharmaceuticals logo. It specifies one unit per package and that the product is Rx only.*

FDA Label Image

Chemical Structure (Rivastigmine 01)

Chemical structure of Rivastigmine, showing molecular components including a carbamate group attached to a benzene ring with methyl substitutions.*

FDA Label Image

Figure 1 (Rivastigmine 02)

A cross-sectional diagram of the Rivastigmine Transdermal System patch illustrating its four distinct layers, with labeled arrows pointing to dimples on the patch surface. The image provides a structural view of the extended-release transdermal delivery system.*

FDA Label Image

Figure 2 (Rivastigmine 03)

A line graph showing rivastigmine plasma concentration (ng/mL) over time (hours) for three dosage strengths: 13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours. The x-axis represents time up to 24 hours, and the y-axis shows rivastigmine levels from 0 to 20 ng/mL with error bars indicating variability.*

FDA Label Image

Figure 3 (Rivastigmine 04)

A line graph showing least square mean changes from baseline ADAS-cog ratings over 24 weeks during treatment. The graph compares Rivastigmine Transdermal System at 9.5 mg/24h and 17.4 mg/24h, capsules 6 mg BID, and placebo. The y-axis indicates clinical improvement and decline, while the x-axis represents weeks during treatment with data points at 0, 16, and 24 weeks.*

FDA Label Image

Figure 4 (Rivastigmine 05)

A bar graph presenting the percentage of patients by ADCS-CGIC rating categories with treatments: Rivastigmine Transdermal System 17.4 mg/24 hours, 9.5 mg/24 hours, capsules 6 mg BID, and placebo. Categories range from Markedly Improved to Markedly Worse, showing distribution of patient responses across these treatment groups.*

FDA Label Image

Figure 5 (Rivastigmine 06)

A line graph depicting the ADCS-IADL change from baseline over weeks of treatment for Rivastigmine Transdermal System at 13.3 mg/24hr and 9.5 mg/24hr doses. The y-axis shows clinical improvement to decline, while the x-axis shows treatment duration up to 48 weeks. Data points include error bars representing LS means SEM.*

FDA Label Image

Figure 6 (Rivastigmine 07)

A line graph showing ADAS-Cog change from baseline (least squares means and SEM) over 48 weeks of treatment for Rivastigmine transdermal systems at 13.3 mg/24hr and 9.5 mg/24hr doses. The y-axis indicates clinical improvement versus decline, with two curves illustrating cognitive changes over time for each dose strength.*

FDA Label Image

Figure 7 (Rivastigmine 08)

A line graph comparing the least squares mean change with standard errors over 24 weeks of treatment for Rivastigmine Transdermal System at 15 cm² and 5 cm² patch sizes. The graph shows clinical improvement or decline, with significant changes noted at weeks 16 and 24 for both patch sizes.*

FDA Label Image

Figure 8 (Rivastigmine 09)

A line graph comparing the least squares mean change ± standard error (STE) over 24 weeks of treatment for two strengths of Rivastigmine Transdermal System: 15 cm² and 5 cm² patches. The graph shows mean differences at 8, 16, and 24 weeks with confidence intervals and p-values, indicating clinical improvement or decline over time for each group.*

FDA Label Image

Figure A (Rivastigmine 10)

An instructional diagram showing the Rivastigmine Transdermal System patch packaging and components. It depicts a pouch labeled with product information, a round patch with Rivastigmine labeled on the adhesive medicine side, protective liners on both sides, and the outside backing. The image visually explains the structure and packaging of the patch.*

FDA Label Image

Figure B (Rivastigmine 11)

An instructional diagram showing possible application sites for the Rivastigmine Transdermal System 9.5 mg/24h patch. It illustrates placement options on the left or right upper arm (side), left or right side of the chest (front), left or right upper back, and left or right lower back, each marked with a shaded rectangular area.*

FDA Label Image

Figure C (Rivastigmine 12)

An instructional illustration depicting a hand holding a Bryant Ranch Prepack Rivastigmine Transdermal System patch packet. The packet is partially opened, showing how to peel it open from the edges, intended for transdermal delivery. The patch is labeled for prescription use only.*

FDA Label Image

Figure D (Rivastigmine 13)

An instructional illustration showing a person's hands peeling the protective liners off the sticky surface of a transdermal patch, likely demonstrating how to prepare the Rivastigmine Transdermal System, 9.5 mg/24h patch, for application.*

FDA Label Image

Figure E (Rivastigmine 14)

An instructional illustration showing the application of the Rivastigmine Transdermal System patch to the upper back of a person. One hand is holding the patch, while the other hand is pressing the patch onto the skin, demonstrating proper placement for transdermal delivery.*

FDA Label Image

Figure F (Rivastigmine 15)

An instructional diagram depicting the application of a Rivastigmine Transdermal System patch on the upper back of a person. The illustration shows a hand placing the patch on the skin between the shoulder blades, demonstrating proper placement for the transdermal patch.*

FDA Label Image

Figure G (Rivastigmine 16)

An instructional illustration showing a person applying a Rivastigmine Transdermal System patch to the upper chest area below the collarbone. The diagram focuses on the correct placement and application method of the transdermal patch on the skin.*

FDA Label Image

Figure H (Rivastigmine 17)

An instructional diagram showing proper disposal of a Rivastigmine Transdermal System 9.5 mg/24h patch. The first panel illustrates folding the sticky sides of the used patch together. The second panel shows sliding the folded patch into its original empty pouch. The third panel depicts placing the pouch in a trash receptacle, with a note to keep it away from children and pets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.